C4 Therapeutics Announces 2023 Strategic Priorities to Advance Portfolio of Targeted Protein Degradation Medicines
January 09, 2023 07:00 ET
|
C4 Therapeutics, Inc.
Phase 1/2 Trial of CFT7455, an IKZF1/3 MonoDAC™ Degrader, Continues to Progress with Phase 1 Dose Escalation Data Expected in 2H 2023; Enrollment Open for Arm Evaluating CFT7455 in Combination with...
C4 Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 03, 2023 07:00 ET
|
C4 Therapeutics, Inc.
WATERTOWN, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science...
C4 Therapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights
November 03, 2022 07:00 ET
|
C4 Therapeutics, Inc.
The Phase 1/2 Clinical Trials of CFT7455, an IKZF1/3 MonoDAC™ Degrader, and CFT8634, a BRD9 BiDAC™ Degrader, Continue to Enroll Patients and Advance Through Dose Escalation IND Clearance Achieved for...
C4 Therapeutics Receives Study May Proceed Letter from U.S. FDA to Initiate Phase 1/2 Clinical Trial of CFT1946, an Orally Bioavailable BiDAC™ Degrader, in BRAF-V600 Mutant Solid Cancers
September 29, 2022 07:00 ET
|
C4 Therapeutics, Inc.
WATERTOWN, Mass., Sept. 29, 2022 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation...
C4 Therapeutics to Present at Bank of America Securities Precision Oncology Conference 2022
September 26, 2022 07:00 ET
|
C4 Therapeutics, Inc.
WATERTOWN, Mass., Sept. 26, 2022 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation...
C4 Therapeutics Reports Second Quarter 2022 Financial Results and Recent Business Highlights
August 04, 2022 08:00 ET
|
C4 Therapeutics, Inc.
– CFT7455, a Novel IKZF1/3 Degrader, Advancing Through Dose Escalation Portion of Phase 1/2 Clinical Trial – – Phase 1/2 Clinical Trial for CFT8634, a BRD9 Degrader, Enrolling Patients and...
C4 Therapeutics Appoints Experienced Clinical Development Leaders Laura Bessen, M.D. and Donna Grogan, M.D. to Board of Directors
August 02, 2022 08:00 ET
|
C4 Therapeutics, Inc.
– Dr. Laura Bessen Brings More Than Two Decades of Experience Across Medical Affairs and Clinical Development in Support of Successful Product Launches – – Dr. Donna Grogan Joins as Accomplished Drug...
C4 Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating CFT8634, an Orally Bioavailable BiDAC™ Degrader for the Treatment of Synovial Sarcoma and SMARCB1-null Tumors
May 16, 2022 08:00 ET
|
C4 Therapeutics, Inc.
WATERTOWN, Mass., May 16, 2022 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science...
C4 Therapeutics Reports First Quarter 2022 Financial Results and Recent Business Highlights
May 05, 2022 08:00 ET
|
C4 Therapeutics, Inc.
– Data from Ongoing CFT7455 Phase 1/2 Trial Presented at the American Association for Cancer Research (AACR) Annual Meeting; Enrollment Continues in Cohorts B1 and C – – Phase 1/2 Clinical Trial...
C4 Therapeutics Presents Clinical Data from Cohort A of the Ongoing Phase 1/2 Clinical Trial of CFT7455, a Novel IKZF1/3 Degrader
April 08, 2022 13:00 ET
|
C4 Therapeutics, Inc.
– Single Agent CFT7455 Induces Deep and Durable Degradation of IKZF1/3 and Meaningful Decreases in Serum Free Light Chain at Doses Lower than Expected Based on Pre-clinical Studies – – CFT7455...